Glenmark launches atovaquone and proguanil hydrochloride in US

Glenmark Pharmaceuticals has launched atovaquone and proguanil hydrochloride in the US, which are used for treatment of malaria. Atovaquone and Proguanil hydrochloride tablets are generic equivalent of GlaxoSmithKline's brand Malarone.

In April 2010, the Indian drugmaker had settled a patent litigation with GlaxoSmithKline, which allowed Glenmark to launch the generic tablets in the US on royalty-bearing licence in the third quarter of calendar year 2011. Malarone had sales of $56 million in 2009 in the US.

Recently, the company’s subsidiary - Glenmark Generics had been granted final approval for their abbreviated new drug application (ANDA) by the United States Food and Drug Administration (USFDA) for Zolmitriptan, generic version of IPR’s migraine treatment Zomig tablets.

Glenmark Pharmecuaticals is research driven globally integrated pharmaceuticals company headquartered in Mumbai. It is leading player in the discovery of new molecules both NCEs (New chemical entity) and NBEs (New biological entity).